Stock Analysis
- India
- /
- Healthcare Services
- /
- NSEI:LALPATHLAB
Dr. Lal PathLabs Full Year 2024 Earnings: In Line With Expectations
Dr. Lal PathLabs (NSE:LALPATHLAB) Full Year 2024 Results
Key Financial Results
- Revenue: ₹5.64b (down 72% from FY 2023).
- Net income: ₹845.0m (down 65% from FY 2023).
- Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by lower expenses.
- EPS: ₹10.13 (down from ₹28.82 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dr. Lal PathLabs Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in India.
Performance of the Indian Healthcare industry.
The company's shares are up 1.3% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 2 warning signs for Dr. Lal PathLabs that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Dr. Lal PathLabs is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:LALPATHLAB
Dr. Lal PathLabs
Engages in the operation of laboratories for carrying out pathological investigations in India and internationally.
Solid track record with excellent balance sheet.